Back to Journals » Pharmacogenomics and Personalized Medicine

Pharmacogenomics and Personalized Medicine


Journal Articles:

- 485 records -

Psoriasis Patients with Specific HLA-Cw Alleles and Lower Plasma IL-17 Level Show Improved Response to Topical Lindioil Treatment

Lin YK, Wang CY, Huang YH, Chang YC, Chen CB, Wang CW, Hui RCY, Chung WH

Pharmacogenomics and Personalized Medicine 2022, 15:515-524

Published Date: 13 May 2022

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran

Di Stefano V, Fava A, Gentile L, Guaraldi P, Leonardi L, Poli L, Tagliapietra M, Vastola M, Fanara S, Ferrero B, Giorgi M, Perfetto F, Russo M, Russo D

Pharmacogenomics and Personalized Medicine 2022, 15:499-514

Published Date: 12 May 2022

Genetic Variations of CARMN Modulate Glioma Susceptibility and Prognosis in a Chinese Han Population

Xi M, Zhang G, Wang L, Chen H, Gao L, Zhang L, Yang Z, Shi H

Pharmacogenomics and Personalized Medicine 2022, 15:487-497

Published Date: 11 May 2022

Correlation Between Angiotensin Receptor Type 1 Polymorphisms and Atherosclerotic Cerebral Infarction Risk

Chen L, Wang Y, Wang Y, Huang S, Wu Z, He J, Zhong W, Zhao B, Ma G, Li Y

Pharmacogenomics and Personalized Medicine 2022, 15:477-485

Published Date: 11 May 2022

Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report

Jeiziner C, Allemann SS, Hersberger KE, Meyer zu Schwabedissen HE

Pharmacogenomics and Personalized Medicine 2022, 15:465-475

Published Date: 9 May 2022

Missense Variant rs28362680 in BTNL2 Reduces Risk of Coronary Heart Disease

Zhuo J, Wu Y, Li W, Li Z, Ding Y, Jin T

Pharmacogenomics and Personalized Medicine 2022, 15:449-464

Published Date: 6 May 2022

Susceptibility of Genetic Variations in Methylation Pathway to Gastric Cancer

Xiong M, Pan B, Wang X, Nie J, Pan Y, Sun H, Xu T, Cho WCS, Wang S, He B

Pharmacogenomics and Personalized Medicine 2022, 15:441-448

Published Date: 4 May 2022

Knowledge, Attitudes and Practices of Pharmacogenomics Among Senior Pharmacy Students: A Cross Sectional Study from Punjab, Pakistan

Shah S, Hanif M, Khan HU, Khan FU, Abbas G, Khurram H, Khames A, Abdelgawad MA, Said AS, Abourehab MAS, Maheen S, Chand UR, Haris M

Pharmacogenomics and Personalized Medicine 2022, 15:429-439

Published Date: 25 April 2022

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy

Bocchia M, Carella AM, Mulè A, Rizzo L, Turrini M, Abbenante MC, Cairoli R, Calafiore V, Defina M, Gardellini A, Luzi G, Patti C, Pinazzi MB, Riva M, Rossi G, Sammartano V, Rigacci L

Pharmacogenomics and Personalized Medicine 2022, 15:393-407

Published Date: 22 April 2022

Association of Long Non-Coding RNAs (lncRNAs) ANRIL and MALAT1 Polymorphism with Cervical Cancer

Yao Y, Liang Y, Dong X, Liu S, Zhang S, Liu W, Li Y, Shi L, Yan Z, Yao Y

Pharmacogenomics and Personalized Medicine 2022, 15:359-375

Published Date: 21 April 2022

Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients: A Pilot Study

Cen H, Wen QW, Zhang HQ, Yu H, Zeng Z, Jin T, Wang TH, Qin W, Huang H, Wu XD

Pharmacogenomics and Personalized Medicine 2022, 15:327-339

Published Date: 12 April 2022

The Impact of BCL11A Polymorphisms on Endometrial Cancer Risk Among Chinese Han Females

Cai J, Peng S, Wang H, Bao S

Pharmacogenomics and Personalized Medicine 2022, 15:311-325

Published Date: 7 April 2022

ABCA7 rs3764650 Polymorphism is Associated with Delayed Neurocognitive Recovery

Yu L, Ji H, Zhou M, Guo Y, Liu J, Lei D, Han C, Ma T

Pharmacogenomics and Personalized Medicine 2022, 15:301-309

Published Date: 30 March 2022

DNTTIP2 Expression is Associated with Macrophage Infiltration and Malignant Characteristics in Low-Grade Glioma

Liu YJ, Zeng SH, Qian WH, Tao MX, Zhu YY, Li JP

Pharmacogenomics and Personalized Medicine 2022, 15:261-275

Published Date: 24 March 2022

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Fontana V, Turner RM, Francis B, Yin P, Pütz B, Hiltunen TP, Ruotsalainen S, Kontula KK, Müller-Myhsok B, Pirmohamed M

Pharmacogenomics and Personalized Medicine 2022, 15:249-260

Published Date: 22 March 2022

The Single Nucleotide Polymorphisms of AP1S1 are Associated with Risk of Esophageal Squamous Cell Carcinoma in Chinese Population

Su F, Fang Y, Yu J, Jiang T, Lin S, Zhang S, Lv L, Long T, Pan H, Qi J, Zhou Q, Tang W, Ding G, Wang L, Tan L, Yin J

Pharmacogenomics and Personalized Medicine 2022, 15:235-247

Published Date: 17 March 2022

Increased Risk of Acute Lymphoblastic Leukemia in Adult Patients with GSTM1 Null Genetic Polymorphism

Abdalhabib EK, Alzahrani B, Alanazi F, Algarni A, Ibrahim IK, Mohamed HA, Hamali HA, Mobarki AA, Dobie G, Saboor M

Pharmacogenomics and Personalized Medicine 2022, 15:227-234

Published Date: 15 March 2022

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Yu F, Li Q, Wang L, Zhao H, Wu H, Yang S, Tang Y, Xiao J, Zhang F

Pharmacogenomics and Personalized Medicine 2022, 15:195-203

Published Date: 10 March 2022

MicroRNA Dysregulation in Prostate Cancer

Schitcu VH, Raduly L, Nutu A, Zanoaga O, Ciocan C, Munteanu VC, Cojocneanu R, Petrut B, Coman I, Braicu C, Berindan-Neagoe I

Pharmacogenomics and Personalized Medicine 2022, 15:177-193

Published Date: 10 March 2022

Associations of SMAD4 rs10502913 and NLRP3 rs1539019 Polymorphisms with Risk of Coal Workers’ Pneumoconiosis Susceptibility in Chinese Han Population

Zhao H, Huang Y, Wang H, Zhao J, Tian S, Bai H, Guo M, Dong C, Shi Y, Li X, Zhu C, Feng T, Ma X, Hou Z

Pharmacogenomics and Personalized Medicine 2022, 15:167-175

Published Date: 4 March 2022

Prediction of Tacrolimus Dose/Weight-Adjusted Trough Concentration in Pediatric Refractory Nephrotic Syndrome: A Machine Learning Approach

Mo X, Chen X, Wang X, Zhong X, Liang H, Wei Y, Deng H, Hu R, Zhang T, Chen Y, Gao X, Huang M, Li J

Pharmacogenomics and Personalized Medicine 2022, 15:143-155

Published Date: 22 February 2022

DNA Methylation Level of Transcription Factor Binding Site in the Promoter Region of Acyl-CoA Synthetase Family Member 3 (ACSF3) in Saudi Autistic Children

Algothmi K, Alqurashi A, Alrofaidi A, Alharbi M, Farsi R, Alburae N, Ganash M, Azhari S, Basingab F, Almuhammadi A, Alqosaibi A, Alkhatabi H, Elaimi A, Jan M, Aldhalaan H, Alrafiah A, Alhazmi S

Pharmacogenomics and Personalized Medicine 2022, 15:131-142

Published Date: 18 February 2022

Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia

Vanwong N, Tipnoppanon S, Na Nakorn C, Srisawasdi P, Rodcharoen P, Medhasi S, Chariyavilaskul P, Siwamogsatham S, Vorasettakarnkij Y, Sukasem C

Pharmacogenomics and Personalized Medicine 2022, 15:119-130

Published Date: 17 February 2022

GABRA1 and GABRB2 Polymorphisms are Associated with Propofol Susceptibility

Zeng Y, Cao S, Chen M, Fang C, Ouyang W

Pharmacogenomics and Personalized Medicine 2022, 15:105-117

Published Date: 9 February 2022

Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis

Haq I, Almulhem M, Soars S, Poulton D, Brodlie M

Pharmacogenomics and Personalized Medicine 2022, 15:91-104

Published Date: 5 February 2022

Clopidogrel Use and CYP2C19 Genotypes in Patients Undergoing Vascular Intervention Procedure: A Hospital-Based Study

Liao YJ, Hsiao TH, Lin CH, Hsu CS, Chang YL, Chen YW, Hsu CY, Chen YM, Wu MF

Pharmacogenomics and Personalized Medicine 2022, 15:81-89

Published Date: 2 February 2022

The Effect of SOCS2 Polymorphisms on Type 2 Diabetes Mellitus Susceptibility and Diabetic Complications in the Chinese Han Population

Pan J, Tong R, Deng Q, Tian Y, Wang N, Peng Y, Fei S, Zhang W, Cui J, Guo C, Yao J, Wei C, Xu J

Pharmacogenomics and Personalized Medicine 2022, 15:65-79

Published Date: 29 January 2022

An Analysis of the Pathogenic Genes and Mutation Sites of Macrodactyly

Li JF, Tian GL, Pan H, Zhang WT, Li DC, Liu JD, Zhao L, Li HL

Pharmacogenomics and Personalized Medicine 2022, 15:55-64

Published Date: 29 January 2022

Genetic and Psychosocial Risk Factors Associated with Suicide Among Community Veterans: Implications for Screening, Treatment and Precision Medicine

Boscarino JA, Adams RE, Urosevich TG, Hoffman SN, Kirchner HL, Chu X, Shi W, Boscarino JJ, Dugan RJ, Withey CA, Figley CR

Pharmacogenomics and Personalized Medicine 2022, 15:17-27

Published Date: 14 January 2022

Association Between SNPs in the One-Carbon Metabolism Pathway and the Risk of Female Breast Cancer in a Chinese Population

Wang X, Xiong M, Pan B, Cho WC, Zhou J, Wang S, He B

Pharmacogenomics and Personalized Medicine 2022, 15:9-16

Published Date: 11 January 2022

Relationship Between KCNQ1 Polymorphism and Type 2 Diabetes Risk in Northwestern China

Xu J, Zhang W, Song W, Cui J, Tian Y, Chen H, Huang P, Yang S, Wang L, He X, Wang L, Shi B, Cui W

Pharmacogenomics and Personalized Medicine 2021, 14:1731-1751

Published Date: 31 December 2021

Systematic Pan-Cancer Analysis of KIF23 and a Prediction Model Based on KIF23 in Clear Cell Renal Cell Carcinoma (ccRCC)

Bai X, Cao Y, Yan X, Tuoheti K, Du G, Chen Z, Wu H, Guo L, Liu T

Pharmacogenomics and Personalized Medicine 2021, 14:1717-1729

Published Date: 30 December 2021

Fragile X Premutation: Medications, Therapy and Lifestyle Advice

Sodhi DK, Hagerman R

Pharmacogenomics and Personalized Medicine 2021, 14:1689-1699

Published Date: 29 December 2021

Isotretinoin Induced Hyperlipidemia and Impact of Leptin Gene rs 7799039 Polymorphism in Safety of Acne Patients

Mohamed AA, Hassnine A, Elsayed A, Montaser M, Ismail Y, El-Demery A, Sultan E, Abdel Aziz RS, Eldemiry E, Hagag R, El-Kholy AA, Salah E

Pharmacogenomics and Personalized Medicine 2021, 14:1679-1687

Published Date: 24 December 2021

Combined GSTT1 Null, GSTM1 Null and XPD Lys/Lys Genetic Polymorphisms and Their Association with Increased Risk of Chronic Myeloid Leukemia

Abdalhabib EK, Jackson DE, Alzahrani B, Elfaki EM, Hamza A, Alanazi F, Ali EI, Algarni A, Ibrahim IK, Saboor M

Pharmacogenomics and Personalized Medicine 2021, 14:1661-1667

Published Date: 22 December 2021

Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China

Wang Y, Peng L, Lu H, Zhang Z, Xing S, Li D, He C, Jin T, Wang L

Pharmacogenomics and Personalized Medicine 2021, 14:1647-1660

Published Date: 17 December 2021

RF1 Gene Mutation in Familial Hemophagocytic Lymphohistiocytosis 2: A Family Report and Literature Review

Shi Y, Qiao Z, Bi X, Zhang C, Fu J, Jia Y, Yang G

Pharmacogenomics and Personalized Medicine 2021, 14:1637-1645

Published Date: 16 December 2021

The Landscape of Clinical Implementation of Pharmacogenetic Testing in Central China: A Single-Center Study

Zhang J, Qi G, Han C, Zhou Y, Yang Y, Wang X, Liu S, Zhang X

Pharmacogenomics and Personalized Medicine 2021, 14:1619-1628

Published Date: 14 December 2021

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature

White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Ackland S

Pharmacogenomics and Personalized Medicine 2021, 14:1603-1617

Published Date: 9 December 2021

Apolipoprotein E Gene Polymorphism and Coronary Artery Disease Risk Among Patients in Northwest China

Ma W, Ren X, Zhang L, Dong H, Lu X, Feng W

Pharmacogenomics and Personalized Medicine 2021, 14:1591-1599

Published Date: 7 December 2021

Identification of a Novel VPS13B Mutation in a Chinese Patient with Cohen Syndrome by Whole-Exome Sequencing

Hu X, Huang T, Liu Y, Zhang L, Zhu L, Peng X, Zhang S

Pharmacogenomics and Personalized Medicine 2021, 14:1583-1589

Published Date: 4 December 2021

MicroRNAs as Novel Biomarkers for P2Y12 – Inhibitors Resistance Prediction

Rytkin E, Mirzaev K, Bure I, Akmalova K, Abdullaev S, Kachanova A, Smirnov V, Grishina E, Lyakhova N, Aleshkovich E, Saribekian A, Andreev D, Shabunin A, Sychev D

Pharmacogenomics and Personalized Medicine 2021, 14:1575-1582

Published Date: 2 December 2021

Genetic Variant of PP2A Subunit Gene Confers an Increased Risk of Primary Liver Cancer in Chinese

Wang Y, Huang Q, Huang X, Zhao H, Guan B, Ban K, Zhu X, Ma Z, Tang Y, Su Z, Nong Q

Pharmacogenomics and Personalized Medicine 2021, 14:1565-1574

Published Date: 1 December 2021

Development and Validation of a Prognostic N6-Methyladenosine-Related Immune Gene Signature for Lung Adenocarcinoma

Zhang L, Luo Y, Cheng T, Chen J, Yang H, Wen X, Jiang Z, Li H, Pan C

Pharmacogenomics and Personalized Medicine 2021, 14:1549-1563

Published Date: 30 November 2021

Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients

Cheng F, Li Q, Wang J, Hu M, Zeng F, Wang Z, Zhang Y

Pharmacogenomics and Personalized Medicine 2021, 14:1463-1474

Published Date: 19 November 2021

Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice

Venkatachalapathy P, Padhilahouse S, Sellappan M, Subramanian T, Kurian SJ, Miraj SS, Rao M, Raut AA, Kanwar RK, Singh J, Khadanga S, Mondithoka S, Munisamy M

Pharmacogenomics and Personalized Medicine 2021, 14:1441-1455

Published Date: 13 November 2021

ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer

Wang X, Li Y, Fu J, Zhou K, Wang T

Pharmacogenomics and Personalized Medicine 2021, 14:1425-1440

Published Date: 10 November 2021

Identification of Two Novel DNAAF2 Variants in Two Consanguineous Families with Primary Ciliary Dyskinesia

Lu C, Yang D, Lei C, Wang R, Guo T, Luo H

Pharmacogenomics and Personalized Medicine 2021, 14:1415-1423

Published Date: 10 November 2021

Variation of Genomic Sites Associated with Severe Covid-19 Across Populations: Global and National Patterns

Balanovsky O, Petrushenko V, Mirzaev K, Abdullaev S, Gorin I, Chernevskiy D, Agdzhoyan A, Balanovska E, Kryukov A, Temirbulatov I, Sychev D

Pharmacogenomics and Personalized Medicine 2021, 14:1391-1402

Published Date: 4 November 2021

Exploring the Epigenetic Regulatory Role of m6A-Associated SNPs in Type 2 Diabetes Pathogenesis

Chen M, Lin W, Yi J, Zhao Z

Pharmacogenomics and Personalized Medicine 2021, 14:1369-1378

Published Date: 27 October 2021

Pattern Recognition Molecules of Lectin Complement Pathway in Ischemic Stroke

Tsakanova G, Stepanyan A, Steffensen R, Soghoyan A, Jensenius JC, Arakelyan A

Pharmacogenomics and Personalized Medicine 2021, 14:1347-1368

Published Date: 21 October 2021

H/ACA snoRNP Gene Family as Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma

Zhang M, Zhao W, Liu S, Liu H, Liu L, Peng Q, Du C, Jiang N

Pharmacogenomics and Personalized Medicine 2021, 14:1331-1345

Published Date: 19 October 2021

NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy

Pai AA, Mohan A, Benjamin ESB, Illangeswaran RSS, Xavier Raj I, Janet NB, Arunachalam AK, Kavitha ML, Kulkarni U, Devasia AJ, Fouzia NA, Abraham A, Srivastava A, George B, Mathews V, Korula A, Balasubramanian P

Pharmacogenomics and Personalized Medicine 2021, 14:1303-1313

Published Date: 2 October 2021

Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

Park JE, Hong MJ, Lee SY, Lee JH, Choi JE, Kang HG, Do SK, Jeong JY, Shin KM, Lee WK, Choi SH, Lee YH, Seo HW, Yoo SS, Lee J, Cha SI, Kim CH, Park JY

Pharmacogenomics and Personalized Medicine 2021, 14:1291-1302

Published Date: 1 October 2021

Analysis of Very Important Pharmacogenomics Variants in the Chinese Lahu Population

Cheng Y, Li Q, Yang X, Ding H, Chen W, Dai R, Zhang C

Pharmacogenomics and Personalized Medicine 2021, 14:1275-1289

Published Date: 1 October 2021

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

Romero-Lorca A, Novillo A, Gaibar M, Gilsanz MF, Galán M, Beltrán L, Antón B, Malón D, Moreno A, Fernández-Santander A

Pharmacogenomics and Personalized Medicine 2021, 14:1263-1273

Published Date: 29 September 2021

The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy

He J, Wang Z, Wang Y, Zou T, Li XP, Cao L, Chen J

Pharmacogenomics and Personalized Medicine 2021, 14:1193-1203

Published Date: 18 September 2021

The Effects of Gene Variations of GABRA2, GABRB1, GABRG2, GAD1 and SLC1A3 on Patients with Propofol During Anesthesia Induction

Zhang L, Zheng Z, Ma W, Zhang S, Xue F, Wang H, He Y, Ye F, Zhou S, Wen Y, Li X, Huang W, Huang M, Li J, Wang Z

Pharmacogenomics and Personalized Medicine 2021, 14:1185-1192

Published Date: 17 September 2021

DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis

Liu YJ, Li JP, Zeng SH, Han M, Liu SL, Zou X

Pharmacogenomics and Personalized Medicine 2021, 14:1151-1168

Published Date: 16 September 2021

Gephyrin and CYP2C9 Genetic Polymorphisms in Patients with Pharmacoresistant Epilepsy

El-Tallawy HN, Abuhamdah S, Nassar AY, Farghaly WMA, Saleem TH, Atta SA, Sayed AA, Tohamy AM, Hassan MH

Pharmacogenomics and Personalized Medicine 2021, 14:1133-1140

Published Date: 9 September 2021

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients

Boiko AS, Pozhidaev IV, Paderina DZ, Bocharova AV, Mednova IA, Fedorenko OY, Kornetova EG, Loonen AJM, Semke AV, Bokhan NA, Ivanova SA

Pharmacogenomics and Personalized Medicine 2021, 14:1123-1131

Published Date: 7 September 2021

Incidence and Risk Factors of Lower-Extremity Deep Vein Thrombosis After Thrombolysis Among Patients with Acute Ischemic Stroke

Liu Z, Liu D, Guo ZN, Jin H, Sun T, Ni C, Yan X

Pharmacogenomics and Personalized Medicine 2021, 14:1107-1114

Published Date: 4 September 2021

Interactive Association Between CYP2C9 rs2860905 Polymorphism and Atrial Fibrillation on Ischemic Stroke in Taiwan Biobank Participants

Peng JW, Nfor ON, Ho CC, Hsu SY, Lung CC, Tantoh DM, Chou MC, Liaw YP

Pharmacogenomics and Personalized Medicine 2021, 14:1087-1092

Published Date: 31 August 2021

Association of Genetic Variants in miR-217 Gene with Risk of Coronary Artery Disease: A Case–Control Study

Han X, Liang X, Wu M, Zhang L, Jiang H

Pharmacogenomics and Personalized Medicine 2021, 14:1081-1086

Published Date: 28 August 2021

Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management

Eljilany I, Elarref M, Shallik N, Elzouki AN, Bader L, El-Bardissy A, Abdelsamad O, Al-Badriyeh D, Cavallari LH, Elewa H

Pharmacogenomics and Personalized Medicine 2021, 14:1069-1080

Published Date: 28 August 2021

A Chinese Boy with Mowat–Wilson Syndrome Caused by a 10 bp Deletion in the ZEB2 Gene

Wei L, Han X, Li X, Han B, Nie W

Pharmacogenomics and Personalized Medicine 2021, 14:1041-1045

Published Date: 23 August 2021

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

He C, Peng L, Xing S, Li D, Wang L, Jin T

Pharmacogenomics and Personalized Medicine 2021, 14:1027-1040

Published Date: 16 August 2021

Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients

Carrascal-Laso L, Franco-Martín M, Marcos-Vadillo E, Ramos-Gallego I, García-Berrocal B, Mayor-Toranzo E, Sánchez-Iglesias S, Lorenzo C, Sevillano-Jiménez A, Sánchez-Martín A, García-Salgado MJ, Isidoro-García M

Pharmacogenomics and Personalized Medicine 2021, 14:1015-1025

Published Date: 16 August 2021

Long Non-Coding RNAs Gene Variants as Molecular Markers for Diabetic Retinopathy Risk and Response to Anti-VEGF Therapy

Mohammad HMF, Abdelghany AA, Al Ageeli E, Kattan SW, Hassan R, Toraih EA, Fawzy MS, Mokhtar N

Pharmacogenomics and Personalized Medicine 2021, 14:997-1014

Published Date: 14 August 2021

Genetic Variation of Inflammatory Genes to Ischemic Stroke Risk in a Chinese Han Population

Zhang Z, Mei Y, Xiong M, Lu F, Zhao X, Zhu J, He B

Pharmacogenomics and Personalized Medicine 2021, 14:977-986

Published Date: 13 August 2021

Individualized Drugs’ Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process

Borro M, Gentile G, Preissner SH, Pomes LM, Gohlke BO, Del Casale A, Eckert A, Marchetti P, Preissner S, Preissner R, Simmaco M

Pharmacogenomics and Personalized Medicine 2021, 14:955-962

Published Date: 5 August 2021

Ovarian Sertoli-Leydig Cell Tumor, Multinodular Goiter, Cystic Nephromas and DICER1 Mutations: Case Report and Literature Review

Ni Y, Zhou X, Wu L, Wu P, Liu Y, Li Y, Cai L, Fu X, Zhang C

Pharmacogenomics and Personalized Medicine 2021, 14:947-953

Published Date: 3 August 2021

Prognostic Role and Potential Mechanisms of the Ferroptosis-Related Metabolic Gene Signature in Hepatocellular Carcinoma

Dai T, Li J, Lu X, Ye L, Yu H, Zhang L, Deng M, Zhu S, Liu W, Wang G, Yang Y

Pharmacogenomics and Personalized Medicine 2021, 14:927-945

Published Date: 3 August 2021

Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients

Chamnanphon M, Sukprasong R, Gaedigk A, Manosuthi W, Chariyavilaskul P, Wittayalertpanya S, Koomdee N, Jantararoungtong T, Puangpetch A, Sukasem C

Pharmacogenomics and Personalized Medicine 2021, 14:915-926

Published Date: 24 July 2021

C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease

Henes JK, Groga-Bada P, Schaeffeler E, Winter S, Hack L, Zdanyte M, Mueller K, Droppa M, Stimpfle F, Gawaz M, Langer H, Schwab M, Geisler T, Rath D

Pharmacogenomics and Personalized Medicine 2021, 14:893-903

Published Date: 21 July 2021

Independent Community Pharmacists’ Experience in Offering Pharmacogenetic Testing

Haga SB, Mills R, Moaddeb J, Liu Y, Voora D

Pharmacogenomics and Personalized Medicine 2021, 14:877-886

Published Date: 15 July 2021

Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV

Jin Y, Jin G, Zhao J, Jiang C, Zhao L, Jiang Y, Chen F, Li H, Wang W, Wu Y, Liu G, Li X, Gu M, Li X, Li Q

Pharmacogenomics and Personalized Medicine 2021, 14:867-875

Published Date: 15 July 2021

Bioinformatics Analysis of Neuroblastoma miRNA Based on GEO Data

Shi J, Zhang P, Su H, Cai L, Zhao L, Zhou H

Pharmacogenomics and Personalized Medicine 2021, 14:849-858

Published Date: 13 July 2021

Interactive Association Between Intronic Polymorphism (rs10506151) of the LRRK2 Gene and Type 2 Diabetes on Neurodegenerative Diseases

Huang MH, Liu YF, Nfor ON, Hsu SY, Lin WY, Chang YS, Liaw YP

Pharmacogenomics and Personalized Medicine 2021, 14:839-847

Published Date: 13 July 2021

Identification of Underlying Hub Genes Associated with Hypertrophic Cardiomyopathy by Integrated Bioinformatics Analysis

Ma Z, Wang X, Lv Q, Gong Y, Xia M, Zhuang L, Lu X, Yang Y, Zhang W, Fu G, Ye Y, Lai D

Pharmacogenomics and Personalized Medicine 2021, 14:823-837

Published Date: 12 July 2021

Single-Nucleotide Polymorphisms Related to Leprosy Risk and Clinical Phenotypes Among Chinese Population

Long SY, Wang L, Jiang HQ, Shi Y, Zhang WY, Xiong JS, Sun PW, Chen YQ, Mei YM, Pan C, Ge G, Wang ZZ, Wu ZW, Yu MW, Wang HS

Pharmacogenomics and Personalized Medicine 2021, 14:813-821

Published Date: 12 July 2021

Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting

Haga SB, Mills R, Moaddeb J, Liu Y, Voora D

Pharmacogenomics and Personalized Medicine 2021, 14:785-796

Published Date: 9 July 2021

Integrative DNA Methylation and Gene Expression Analysis of Cognitive Behavioral Therapy Response in Children and Adolescents with Obsessive-Compulsive Disorder; a Pilot Study

Rodriguez N, Martinez-Pinteño A, Blázquez A, Ortiz AE, Moreno E, Gassó P, Lafuente A, Lazaro L, Mas S

Pharmacogenomics and Personalized Medicine 2021, 14:757-766

Published Date: 29 June 2021

A Two-Stage Study Identifies Two Novel Polymorphisms in PRKAG2 Affecting Metformin Response in Chinese Type 2 Diabetes Patients

Xiao D, Liu JY, Zhang SM, Liu RR, Yin JY, Han XY, Li X, Zhang W, Chen XP, Zhou HH, Ji LN, Liu ZQ

Pharmacogenomics and Personalized Medicine 2021, 14:745-755

Published Date: 23 June 2021

Acetylator Status Among Newly Diagnosed and Recurrent Tuberculosis Patients from Kupang, Eastern Part of Indonesia

Sahiratmadja E, Rini IA, Penggoam S, Charles A, Maskoen AM, Parwati I

Pharmacogenomics and Personalized Medicine 2021, 14:737-744

Published Date: 22 June 2021

The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma

He F, Song K, Guan G, Huo J, Xin Y, Li T, Liu C, Zhu Q, Fan N, Guo Y, Wu L

Pharmacogenomics and Personalized Medicine 2021, 14:723-736

Published Date: 21 June 2021

Physicians’ Knowledge and Attitudes Regarding Point-of-Care Pharmacogenetic Testing: A Hospital-Based Cross-Sectional Study

Muflih S, Alshogran OY, Al-Azzam S, Al-Taani G, Khader YS

Pharmacogenomics and Personalized Medicine 2021, 14:655-665

Published Date: 1 June 2021

Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview

Svob Strac D, Konjevod M, Sagud M, Nikolac Perkovic M, Nedic Erjavec G, Vuic B, Simic G, Vukic V, Mimica N, Pivac N

Pharmacogenomics and Personalized Medicine 2021, 14:631-653

Published Date: 28 May 2021

Angiotensin System Polymorphisms’ in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study

Cafiero C, Rosapepe F, Palmirotta R, Re A, Ottaiano MP, Benincasa G, Perone R, Varriale E, D'Amato G, Cacciamani A, Micera A, Pisconti S

Pharmacogenomics and Personalized Medicine 2021, 14:621-629

Published Date: 27 May 2021

Ferroptosis-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Diffuse Large B-Cell Lymphoma

Chen H, He Y, Pan T, Zeng R, Li Y, Chen S, Li Y, Xiao L, Zhou H

Pharmacogenomics and Personalized Medicine 2021, 14:609-619

Published Date: 26 May 2021

Association of HMGA2 Polymorphisms with Glioma Susceptibility in Chinese Children

Zhou J, Wang P, Zhang R, Huang X, Dai H, Yuan L, Ruan J

Pharmacogenomics and Personalized Medicine 2021, 14:601-607

Published Date: 25 May 2021

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance

Qiao LY, Li HB, Zhang Y, Shen D, Liu P, Che YQ

Pharmacogenomics and Personalized Medicine 2021, 14:591-599

Published Date: 25 May 2021

Trigger-Specific Remodeling of KCa2 Potassium Channels in Models of Atrial Fibrillation

Rahm AK, Gramlich D, Wieder T, Müller ME, Schoeffel A, El Tahry FA, Most P, Heimberger T, Sandke S, Weis T, Ullrich ND, Korff T, Lugenbiel P, Katus HA, Thomas D

Pharmacogenomics and Personalized Medicine 2021, 14:579-590

Published Date: 20 May 2021

Genetic Association Study Revealed Three Loci Were Associated Risk of Myopia Among Minors

Zhou Z, Li S, Yang Q, Yang X, Hao K, Liu Y, Xu S

Pharmacogenomics and Personalized Medicine 2021, 14:547-551

Published Date: 11 May 2021

Pathway to Ascertain the Role of Pharmacogenomics in Healthcare Utilization Outcomes [Response to Letter]

Takahashi PY, Ryu E, Cerhan JR, Bielinski SJ, Olson JE

Pharmacogenomics and Personalized Medicine 2021, 14:545-546

Published Date: 6 May 2021

BRCA2 3ʹ-UTR Polymorphism rs15869 Alters Susceptibility to Papillary Thyroid Carcinoma via Binding hsa-mir-1178-3p

Guo N, Qu P, Li H, Liu L, Jin H, Liu R, Zhang Z, Zhang X, Li Y, Lu X, Zhao Y

Pharmacogenomics and Personalized Medicine 2021, 14:533-544

Published Date: 6 May 2021

Digital PCR Detection of mtDNA/gDNA Ratio in Embryo Culture Medium for Prediction of Embryo Development Potential

Zhang Q, Ji H, Shi J, Wang L, Ding L, Jiang Y, Huang X, Qiu Snr P, Li P

Pharmacogenomics and Personalized Medicine 2021, 14:521-531

Published Date: 30 April 2021

Evaluation of CYP2C19 Gene Polymorphisms in Patients with Acid Peptic Disorders Treated with Esomeprazole

Díaz-Ordóñez L, Ramírez-Montaño D, Candelo E, González-Restrepo C, Silva-Peña S, Rojas CA, Sepulveda Copete M, Echavarria HR, Pachajoa H

Pharmacogenomics and Personalized Medicine 2021, 14:509-520

Published Date: 29 April 2021

Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene

Wang H, Sui Z, Wu X, Tang P, Zhang H, Yu Z

Pharmacogenomics and Personalized Medicine 2021, 14:497-508

Published Date: 28 April 2021

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects

Liu Y, Yang C, Qi W, Pei Z, Xue W, Zhu H, Dong M, Guo Y, Cong D, Wang F

Pharmacogenomics and Personalized Medicine 2021, 14:477-485

Published Date: 23 April 2021

DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results

Martinez-Pinteño A, Rodriguez N, Blázquez A, Plana MT, Varela E, Gassó P, Lafuente A, Lazaro L, Mas S

Pharmacogenomics and Personalized Medicine 2021, 14:459-467

Published Date: 19 April 2021

CSF1R is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in the Gastric Cancer Microenvironment

Chen D, Xiong L, Zhang L, Yu H, Xu Y, Wang M, Jiang X, Xiong Z

Pharmacogenomics and Personalized Medicine 2021, 14:445-457

Published Date: 13 April 2021

CYP2C9*3/*3 Gene Expression Affects the Total and Free Concentrations of Valproic Acid in Pediatric Patients with Epilepsy

Wu X, Dong W, Li H, Yang X, Jin Y, Zhang Z, Jiang Y

Pharmacogenomics and Personalized Medicine 2021, 14:417-430

Published Date: 9 April 2021

Non-Classical 21-Hydroxylase Deficiency: Analysis of a Mutant Gene in a Uyghur Family and Literature Review

Maimaitiming J, Amuti G, TuHuTi A, Chen Y, Song XX, Wang J, Alimu A, Zhang K, Abudounaiyimu M, Jiang J, Wang XL, Guo YY

Pharmacogenomics and Personalized Medicine 2021, 14:409-416

Published Date: 7 April 2021

CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma

Sun J, Zhu X, Zhao Y, Zhou Q, Qi R, Liu H

Pharmacogenomics and Personalized Medicine 2021, 14:397-408

Published Date: 1 April 2021

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]

Maseng MJ, Tawe L, Thami PK, Seatla KK, Moyo S, Martinelli A, Kasvosve I, Novitsky V, Essex M, Russo G, Gaseitsiwe S, Paganotti GM

Pharmacogenomics and Personalized Medicine 2021, 14:395-396

Published Date: 31 March 2021

Correlation Study on HLA-DR and CD117 (c-Kit) Expressions: Its Prognosis and Treatment Response in Acute Myeloid Leukemia Patients

El-Meligui YM, Abd Elrhman HE, Salahuddin A, Hamouda MA, Kassem AB

Pharmacogenomics and Personalized Medicine 2021, 14:381-393

Published Date: 30 March 2021

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen

Zhu X, Zhu J, Sun F, Zhen Z, Zhou D, Lu S, Huang J, Que Y, Zhang L, Cai R, Wang J, Zhang Y

Pharmacogenomics and Personalized Medicine 2021, 14:369-377

Published Date: 23 March 2021

Skeletal Abnormalities and VDR1 Gene Polymorphisms in Mucopolysaccharidosis Patients

Alkhzouz C, Cabau G, Lazea C, Asavoaie C, Bucerzan S, Mirea AM, Farcas M, Miclaus M Jnr, Popp R, Miclea D

Pharmacogenomics and Personalized Medicine 2021, 14:349-358

Published Date: 17 March 2021

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana

Maseng MJ, Tawe L, Thami PK, Seatla KK, Moyo S, Martinelli A, Kasvosve I, Novitsky V, Essex M, Russo G, Gaseitsiwe S, Paganotti GM

Pharmacogenomics and Personalized Medicine 2021, 14:335-347

Published Date: 16 March 2021

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer

Pacini L, Jenks AD, Vyse S, Wilding CP, Arthur A, Huang PH

Pharmacogenomics and Personalized Medicine 2021, 14:301-317

Published Date: 9 March 2021

Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions

Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer zu Schwabedissen HE

Pharmacogenomics and Personalized Medicine 2021, 14:279-286

Published Date: 19 February 2021

TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy

Song K, He F, Xin Y, Guan G, Huo J, Zhu Q, Fan N, Guo Y, Zang Y, Wu L

Pharmacogenomics and Personalized Medicine 2021, 14:269-278

Published Date: 16 February 2021

Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort

Machado-Rugolo J, Gutierrez Prieto T, Fabro AT, Parra Cuentas ER, Sá VK, Baldavira CM, Rainho CA, Castelli EC, Farhat C, Takagaki TY, Nagai MA, Capelozzi VL

Pharmacogenomics and Personalized Medicine 2021, 14:239-252

Published Date: 15 February 2021

No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study

Takahashi PY, Ryu E, Bielinski SJ, Hathcock M, Jenkins GD, Cerhan JR, Olson JE

Pharmacogenomics and Personalized Medicine 2021, 14:229-237

Published Date: 11 February 2021

Identification of Crucial Genes and Pathways Associated with Atherosclerotic Plaque in Diabetic Patients

Li YY, Zhang S, Wang H, Zhang SX, Xu T, Chen SW, Zhang Y, Chen Y

Pharmacogenomics and Personalized Medicine 2021, 14:211-220

Published Date: 4 February 2021

TPMT Genetic Variability and Its Association with Hematotoxicity in Indonesian Children with Acute Lymphoblastic Leukemia in Maintenance Therapy

Rosdiana DS, Setiabudy R, Andalusia R, Gatot D, Louisa M, Bardosono S, Instiaty I

Pharmacogenomics and Personalized Medicine 2021, 14:199-210

Published Date: 3 February 2021

Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension

Liang H, Zhang X, Ma Z, Sun Y, Shu C, Zhu Y, Zhang Y, Hu S, Fu X, Liu L

Pharmacogenomics and Personalized Medicine 2021, 14:189-197

Published Date: 2 February 2021

Assessment of the Role of Selected SMAD3 and SMAD4 Genes Polymorphisms in the Development of Colorectal Cancer: Preliminary Research

Wosiak A, Wodziński D, Michalska K, Pietrzak J, Kordek R, Balcerczak E

Pharmacogenomics and Personalized Medicine 2021, 14:167-178

Published Date: 29 January 2021

Relationship Between Interleukin-6 −174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients

Sokolik R, Iwaszko M, Świerkot J, Wysoczańska B, Korman L, Wiland P, Bogunia-Kubik K

Pharmacogenomics and Personalized Medicine 2021, 14:157-166

Published Date: 28 January 2021

Genetic Polymorphism Effect on Warfarin–Rifampin Interaction: A Case Report and Review of Literature

Salem M, Eljilany I, El-Bardissy A, Elewa H

Pharmacogenomics and Personalized Medicine 2021, 14:149-156

Published Date: 26 January 2021

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations

Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K

Pharmacogenomics and Personalized Medicine 2021, 14:135-147

Published Date: 27 January 2021

Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon

Fernandes MR, Rodrigues JCG, Maroñas O, Latorre-Pellicer A, Cruz R, Guerreiro JF, Burbano RMR, Assumpção PP, Ribeiro-dos-Santos A, Santos SEB, Carracedo A, Santos NPC

Pharmacogenomics and Personalized Medicine 2021, 14:117-133

Published Date: 22 January 2021

No Association Between FTO Gene Polymorphisms and Central Nervous System Tumor Susceptibility in Chinese Children

Liao Y, Yuan L, Zhang Z, Lin A, Zhou J, Zhuo Z, Zhao J

Pharmacogenomics and Personalized Medicine 2021, 14:109-115

Published Date: 19 January 2021

STAT6 rs324015 Gene Polymorphism Increases Ulcerative Colitis Risk: A Case–Control Study

Dai L, Zhang D, Qian Y, Wan Y, Chang S, Qian H

Pharmacogenomics and Personalized Medicine 2021, 14:101-107

Published Date: 19 January 2021

High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer

Liu Y, Huang S, Kuang M, Wang H, Xie Q

Pharmacogenomics and Personalized Medicine 2021, 14:87-99

Published Date: 18 January 2021

Genetic Interaction of H19 and TGFBR1 Polymorphisms with Risk of Epilepsy in a Chinese Population

Zheng Z, Yan Y, Guo Q, Wang L, Han X, Liu S

Pharmacogenomics and Personalized Medicine 2021, 14:77-86

Published Date: 14 January 2021

Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions

Tong H, Phan NVT, Nguyen TT, Nguyen DV, Vo NS, Le L

Pharmacogenomics and Personalized Medicine 2021, 14:61-75

Published Date: 13 January 2021

Genetic Variants of the MIF Gene and Susceptibility of Rectal Cancer

Chuo D, Lin D, Yin M, Chen Y

Pharmacogenomics and Personalized Medicine 2021, 14:55-60

Published Date: 12 January 2021

Identification of Four Genes as Prognosis Signatures in Lung Adenocarcinoma Microenvironment

Yao Y, Zhang T, Qi L, Liu R, Liu G, Li J, Sun C

Pharmacogenomics and Personalized Medicine 2021, 14:15-26

Published Date: 8 January 2021

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin

Srisawasdi P, Rodcharoen P, Vanavanan S, Chittamma A, Sukasem C, Na nakorn C, Dejthevaporn C, Kroll MH

Pharmacogenomics and Personalized Medicine 2021, 14:1-13

Published Date: 6 January 2021

Single-Nucleotide Polymorphisms in Genes Predisposing to Leprosy in Leprosy Household Contacts in Zhejiang Province, China

Shen YL, Long SY, Kong WM, Wu LM, Fei LJ, Yao Q, Wang HS

Pharmacogenomics and Personalized Medicine 2020, 13:767-773

Published Date: 21 December 2020

Screening and Identifying Cisplatin-Related Gene Mutations in Lung Squamous Cell Carcinoma

Li X, Wang Y, Hu S, Bai Y

Pharmacogenomics and Personalized Medicine 2020, 13:757-766

Published Date: 18 December 2020

Case–Control Study on TNFRSF6B Gene Polymorphism and Susceptibility to Gastric Cancer in a Chinese Han Population

Gu X, Mao Z, Pan H, Zou C, Ding G, Fan Y

Pharmacogenomics and Personalized Medicine 2020, 13:749-756

Published Date: 17 December 2020

A Novel Prognostic Score Based on ZG16 for Predicting CRC Survival

Wang W, Sun JF, Wang XZ, Ying HQ, You XH, Sun F

Pharmacogenomics and Personalized Medicine 2020, 13:735-747

Published Date: 16 December 2020

Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation

Bright D, Saadeh C, DeVuyst-Miller S, Sohn M, Choker A, Langerveld A

Pharmacogenomics and Personalized Medicine 2020, 13:719-724

Published Date: 10 December 2020

Cystic Fibrosis Polymorphic Variants in a Russian Population

Kiseleva A, Klimushina M, Sotnikova E, Skirko O, Divashuk M, Kurilova O, Ershova A, Khlebus E, Zharikova A, Efimova I, Pokrovskaya M, Slominsky PA, Shalnova S, Meshkov A, Drapkina O

Pharmacogenomics and Personalized Medicine 2020, 13:679-686

Published Date: 1 December 2020

Impact of APOE Alleles-by-Diet Interactions on Glycemic and Lipid Features– A Cross-Sectional Study of a Cohort of Type 2 Diabetes Patients from Western Mexico: Implications for Personalized Medicine

Torres-Valadez R, Ramos-Lopez O, Frías Delgadillo KJ, Flores-García A, Rojas Carrillo E, Aguiar-García P, Bernal Pérez JA, Martinez-Lopez E, Martínez JA, Zepeda-Carrillo EA

Pharmacogenomics and Personalized Medicine 2020, 13:655-663

Published Date: 26 November 2020

Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease

AL-Eitan LN, Elsaqa BZ, Almasri AY, Aman HA, Khasawneh RH, Alghamdi MA

Pharmacogenomics and Personalized Medicine 2020, 13:619-632

Published Date: 17 November 2020

Prevalence of CYP2C8*2 and *3 among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment

Habtemikael L, Russom M, Bahta I, Mihreteab S, Berhane A, Mårtensson A, Gil JP

Pharmacogenomics and Personalized Medicine 2020, 13:571-575

Published Date: 12 November 2020

Susceptibility of PON1/PON2 Genetic Variations to Ischemic Stroke Risk in a Chinese Han Population

Pan Y, He B, Sun H, Xu T, Pan B, Wang S, Mei Y

Pharmacogenomics and Personalized Medicine 2020, 13:563-570

Published Date: 29 October 2020

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia

Chamnanphon M, Wainipitapong S, Wiwattarangkul T, Chuchuen P, Nissaipan K, Phaisal W, Tangwongchai S, Sukasem C, Wittayalertpanya S, Gaedigk A, Aniwattanapong D, Chariyavilaskul P

Pharmacogenomics and Personalized Medicine 2020, 13:543-551

Published Date: 2 November 2020

SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population

Rattanacheeworn P, Chamnanphon M, Thongthip S, Kittanamongkolchai W, Townamchai N, Avihingsanon Y, Udomnilobol U, Prueksaritanont T, Jianmongkol S, Chariyavilaskul P

Pharmacogenomics and Personalized Medicine 2020, 13:521-530

Published Date: 22 October 2020

Genetic Association of Epilepsy and Anti-Epileptic Drugs Treatment in Jordanian Patients

AL-Eitan LN, Al-Dalala IM, Elshammari AK, Khreisat WH, Nimiri AF, Alnaamneh AH, Aljamal HA, Alghamdi MA

Pharmacogenomics and Personalized Medicine 2020, 13:503-510

Published Date: 16 October 2020

Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease

Cafiero C, Re A, Micera A, Palmirotta R, Monaco D, Romano F, Fabrizio C, Di Francia R, Cacciamani A, Surico PL, D'Amato G, Pisconti S

Pharmacogenomics and Personalized Medicine 2020, 13:463-484

Published Date: 13 October 2020

Competing Endogenous RNA (ceRNA) Network Analysis of Autophagy-Related Genes in Hepatocellular Carcinoma

Yang C, Wang Y, Xue W, Xie Y, Dong Q, Zhu C

Pharmacogenomics and Personalized Medicine 2020, 13:445-462

Published Date: 13 October 2020

Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review

Afifah NN, Diantini A, Intania R, Abdulah R, Barliana MI

Pharmacogenomics and Personalized Medicine 2020, 13:427-444

Published Date: 8 October 2020

Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine

Zhu G, Dawson E, Huskey A, Gordon RJ, Del Tredici AL

Pharmacogenomics and Personalized Medicine 2020, 13:405-414

Published Date: 30 September 2020

Altered Gene Expression in Acne Vulgaris Patients Treated by Oral Isotretinoin: A Preliminary Study

Jiang Y, Chen H, Han L, Xie X, Zheng Y, Lai W

Pharmacogenomics and Personalized Medicine 2020, 13:385-395

Published Date: 15 September 2020

Carvedilol Alters Circulating MiR-1 and MiR-214 in Heart Failure

Shirazi-Tehrani E, Firouzabadi N, Tamaddon G, Bahramali E, Vafadar A

Pharmacogenomics and Personalized Medicine 2020, 13:375-383

Published Date: 3 September 2020

The Relationship Between Single Nucleotide Polymorphisms of SMAD3/SMAD6 and Risk of Esophageal Squamous Cell Carcinoma in Chinese Population

Yu J, Dong Y, Tang W, Pan H, Lv L, Long T, Zhou Q, Qi J, Liu J, Ding G, Yin J, Tan L

Pharmacogenomics and Personalized Medicine 2020, 13:355-363

Published Date: 24 August 2020

IKBKB rs2272736 is Associated with Gastric Cancer Survival

Gong Y, Zhao W, Jia Q, Dai J, Chen N, Chen Y, Gu D, Huo X, Chen J

Pharmacogenomics and Personalized Medicine 2020, 13:345-352

Published Date: 19 August 2020

IL-6 −572C>G and CARD8 304T>A Genetic Polymorphisms are Associated with the Absolute Neutrophil Count in Patients with Hematological Malignancies Under Chemotherapy: An Application of Multilevel Models to a Preliminary Pharmacogenetic Study

Martinez MF, Alveal E, Soto TG, Bustamante EI, Ávila F, Bangdiwala SI, Flores I, Benavides C, Morales R, Varela NM, Quiñones LA

Pharmacogenomics and Personalized Medicine 2020, 13:337-343

Published Date: 19 August 2020

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia

Maamari D, El-Khoury H, Saifi O, Muwakkit SA, Zgheib NK

Pharmacogenomics and Personalized Medicine 2020, 13:295-317

Published Date: 12 August 2020

miR-100 rs1834306 A>G Increases the Risk of Hirschsprung Disease in Southern Chinese Children

Zhu Y, Lin A, Zheng Y, Xie X, He Q, Zhong W

Pharmacogenomics and Personalized Medicine 2020, 13:283-288

Published Date: 10 August 2020

Polymorphism of XRCC3 in Egyptian Breast Cancer Patients

Alkasaby MK, Abd El-Fattah AI, Ibrahim IH, Abd El-Samie HS

Pharmacogenomics and Personalized Medicine 2020, 13:273-282

Published Date: 6 August 2020

Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network

Duong BQ, Arwood MJ, Hicks JK, Beitelshees AL, Franchi F, Houder JT, Limdi NA, Cook KJ, Owusu Obeng A, Petry N, Tuteja S, Elsey AR, Cavallari LH, Wiisanen K

Pharmacogenomics and Personalized Medicine 2020, 13:217-226

Published Date: 17 July 2020

Analysis of Comprehensive Pharmacogenomic Profiling of VIP Variants Among the Genetically Isolated Chechen Subpopulation from Jordan

AL-Eitan LN, Rababa'h DM, Hakooz NM, Alghamdi MA, Dajani RB

Pharmacogenomics and Personalized Medicine 2020, 13:199-215

Published Date: 14 July 2020

Single Nucleotide Variants Associated with Colorectal Cancer Among Iranian Patients: A Narrative Review

Jamshidi M, Mohammadi Pour S, Mahmoudian-Sani MR

Pharmacogenomics and Personalized Medicine 2020, 13:167-180

Published Date: 3 June 2020

Variations in the Wnt/β-Catenin Pathway Key Genes as Predictors of Cervical Cancer Susceptibility

Wang B, Wang M, Li X, Yang M, Liu L

Pharmacogenomics and Personalized Medicine 2020, 13:157-165

Published Date: 20 May 2020

Negative Association Between lncRNA HOTTIP rs3807598 C>G and Hirschsprung Disease

Zheng Y, Zhuo Z, Xie X, Lu L, He Q, Zhong W

Pharmacogenomics and Personalized Medicine 2020, 13:151-156

Published Date: 6 May 2020

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy

Zhang C, Duan S, Guo M, Yuan Y, Huang Z, Zhu J, Sun B, Zhang B, Xing C

Pharmacogenomics and Personalized Medicine 2020, 13:141-149

Published Date: 23 April 2020

Challenges and Future Prospects of Precision Medicine in Psychiatry

Manchia M, Pisanu C, Squassina A, Carpiniello B

Pharmacogenomics and Personalized Medicine 2020, 13:127-140

Published Date: 23 April 2020

Association Between lncRNA HULC rs7763881 Polymorphism and Gastric Cancer Risk

Hong JH, Jin EH, Chang IA, Kang H, Lee SI, Sung JK

Pharmacogenomics and Personalized Medicine 2020, 13:121-126

Published Date: 9 April 2020

On the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine

Álvarez-Machancoses Ó, DeAndrés Galiana EJ, Cernea A, Fernández de la Viña J, Fernández-Martínez JL

Pharmacogenomics and Personalized Medicine 2020, 13:105-119

Published Date: 19 March 2020

Pharmacogenetics of Pediatric Asthma: Current Perspectives

Perez-Garcia J, Espuela-Ortiz A, Lorenzo-Diaz F, Pino-Yanes M

Pharmacogenomics and Personalized Medicine 2020, 13:89-103

Published Date: 18 March 2020

ADAM17 Genetic Variants and the Response of TNF-α Inhibitor in Rheumatoid Arthritis Patients

Kim HJ, Trinh NT, Choi Y, Kim W, Min KH, Kang SO, Kim JH, Kim HA, Jung JY, Choi IA, Lee KE

Pharmacogenomics and Personalized Medicine 2020, 13:81-88

Published Date: 16 March 2020

Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics

Lopes GS, Bielinski SJ, Moyer AM, Black III JL, Jacobson DJ, Jiang R, Larson NB, St Sauver JL

Pharmacogenomics and Personalized Medicine 2020, 13:71-79

Published Date: 13 March 2020

A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions

Calderon-Ospina CA, Hernández-Sómerson M, García AM, Mejia A, Tamayo-Agudelo C, Laissue P, Fonseca Mendoza DJ

Pharmacogenomics and Personalized Medicine 2020, 13:59-70

Published Date: 2 March 2020

HMGA2 Polymorphisms and Hepatoblastoma Susceptibility: A Five-Center Case-Control Study

Li L, Zhuo Z, Yang Z, Zhu J, He X, Yang Z, Zhang J, Xin Y, He J, Zhang T

Pharmacogenomics and Personalized Medicine 2020, 13:51-57

Published Date: 11 February 2020

Towards Precision Medicine in Systemic Lupus Erythematosus

Lever E, Alves MR, Isenberg DA

Pharmacogenomics and Personalized Medicine 2020, 13:39-49

Published Date: 4 February 2020

CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban

Sychev DA, Baturina OA, Mirzaev KB, Rytkin E, Ivashchenko DV, Andreev DA, Ryzhikova KA, Grishina EA, Bochkov PO, Shevchenko RV

Pharmacogenomics and Personalized Medicine 2020, 13:29-37

Published Date: 23 January 2020

The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children

Pavlovic D, Budic I, Jevtovic Stoimenov T, Stokanovic D, Marjanovic V, Stevic M, Slavkovic M, Simic D

Pharmacogenomics and Personalized Medicine 2020, 13:13-27

Published Date: 17 January 2020

Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine

Chamnanphon M, Gaedigk A, Puangpetch A, Pasomsub E, Chantratita W, Longley RJ, Sattabongkot J, Chariyavilaskul P, Sukasem C

Pharmacogenomics and Personalized Medicine 2020, 13:1-12

Published Date: 10 January 2020

CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese

Chow E, Poon EWM, Fok BSP, Chan JCN, Tomlinson B

Pharmacogenomics and Personalized Medicine 2019, 12:397-401

Published Date: 3 January 2020

Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov–Smirnov Algorithm

Hu RY, Tian XB, Li B, Luo R, Zhang B, Zhao JM

Pharmacogenomics and Personalized Medicine 2019, 12:369-375

Published Date: 11 December 2019

Pharmacogenomics And Hypertension: Current Insights

Oliveira-Paula GH, Pereira SC, Tanus-Santos JE, Lacchini R

Pharmacogenomics and Personalized Medicine 2019, 12:341-359

Published Date: 22 November 2019

Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects

Dorofeeva MN, Shikh EV, Sizova ZM, Tarasenko AV, Denisenko NP, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2019, 12:329-339

Published Date: 5 November 2019

A Novel Mutation Of The EMD Gene In A Family With Cardiac Conduction Abnormalities And A High Incidence Of Sudden Cardiac Death

Kong D, Zhan Y, Liu C, Hu Y, Zhou Y, Luo J, Gu L, Zhou X, Zhang Z

Pharmacogenomics and Personalized Medicine 2019, 12:319-327

Published Date: 31 October 2019

Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare

Giri J, Moyer AM, Bielinski SJ, Caraballo PJ

Pharmacogenomics and Personalized Medicine 2019, 12:305-318

Published Date: 30 October 2019

Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy

Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y

Pharmacogenomics and Personalized Medicine 2019, 12:297-303

Published Date: 21 October 2019

The AKR1D1*36 (rs1872930) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome

Kapedanovska-Nestorovska A, Dimovski AJ, Sterjev Z, Matevska Geskovska N, Suturkova L, Ugurov P, Mitrev Z, Rosalia R

Pharmacogenomics and Personalized Medicine 2019, 12:287-295

Published Date: 21 October 2019

Personalized treatment options for thyroid cancer: current perspectives

Khatami F, Larijani B, Nikfar S, Hasanzad M, Fendereski K, Tavangar SM

Pharmacogenomics and Personalized Medicine 2019, 12:235-245

Published Date: 13 September 2019

Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study

AL-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Al-Quasmi MN, Aljamal HA

Pharmacogenomics and Personalized Medicine 2019, 12:225-233

Published Date: 4 September 2019

The influence of an IL-4 variable number tandem repeat (VNTR) polymorphism on breast cancer susceptibility

AL-Eitan LN, Rababa'h DM, Alghamdi MA, Khasawneh RH

Pharmacogenomics and Personalized Medicine 2019, 12:201-207

Published Date: 26 August 2019

Toxicogenomic analysis of publicly available transcriptomic data can predict food, drugs, and chemical-induced asthma

Hachim MY, Hachim IY, Elemam NM, Hamoudi RA

Pharmacogenomics and Personalized Medicine 2019, 12:181-199

Published Date: 26 August 2019

A personalized approach to acute myeloid leukemia therapy: current options

Illangeswaran RSS, Das S, Paul DZ, Mathews V, Balasubramanian P

Pharmacogenomics and Personalized Medicine 2019, 12:167-179

Published Date: 2 August 2019

Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia

Puangpetch A, Srisawasdi P, Unaharassamee W, Jiratjintana N, Vanavanan S, Punprasit S, Na Nakorn C, Sukasem C, Kroll MH

Pharmacogenomics and Personalized Medicine 2019, 12:155-166

Published Date: 6 August 2019

Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery

Awad H, Ahmed A, Urman RD, Stoicea N, Bergese SD

Pharmacogenomics and Personalized Medicine 2019, 12:145-154

Published Date: 26 July 2019

Update on the pharmacogenomics of pain management

Kaye AD, Garcia AJ, Hall OM, Jeha GM, Cramer KD, Granier AL, Kallurkar A, Cornett EM, Urman RD

Pharmacogenomics and Personalized Medicine 2019, 12:125-143

Published Date: 3 July 2019

Plasma brain-derived neurotrophic factor (BDNF) concentration and the BDNF Val66Met polymorphism in suicide: a prospective study in patients with depressive disorder

Ai M, Wang J, Chen J, Wang W, Xu X, Gan Y, Li X, Gou X, Cao J, Lv Z, Chen X, Wang H, Ma Q, Kuang L

Pharmacogenomics and Personalized Medicine 2019, 12:97-106

Published Date: 2 July 2019

Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients

AL-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Aljamal HA

Pharmacogenomics and Personalized Medicine 2019, 12:87-95

Published Date: 10 June 2019

g-Nomic: a new pharmacogenetics interpretation software

Sabater A, Ciudad CJ, Cendros M, Dobrokhotov D, Sabater-Tobella J

Pharmacogenomics and Personalized Medicine 2019, 12:75-85

Published Date: 29 May 2019

Personalized medicine in breast cancer: pharmacogenomics approaches

Jeibouei S, Akbari ME, Kalbasi A, Aref AR, Ajoudanian M, Rezvani A, Zali H

Pharmacogenomics and Personalized Medicine 2019, 12:59-73

Published Date: 27 May 2019

VKORC1 variants as significant predictors of warfarin dose in Emiratis

Al-Mahayri ZN, Al Jaibeji HS, Saab Y, Soliman K, Al-Gazali L, Patrinos GP, Ali BR

Pharmacogenomics and Personalized Medicine 2019, 12:47-57

Published Date: 17 April 2019

Identification of genetic variants associated with skeletal muscle function deficit in childhood acute lymphoblastic leukemia survivors

Nadeau G, Ouimet-Grennan E, Aaron M, Drouin S, Bertout L, Shalmiev A, Beaulieu P, St-Onge P, Veilleux LN, Rauch F, Petrykey K, Laverdière C, Sinnett D, Alos N, Krajinovic M

Pharmacogenomics and Personalized Medicine 2019, 12:33-45

Published Date: 11 April 2019

Population’s perspectives toward biobanks in scientific research: a study from Jordan

Makhlouf H, Alrabadi N, Khabour OF, Alzoubi KH, Al-Delaimy W

Pharmacogenomics and Personalized Medicine 2019, 12:23-32

Published Date: 21 March 2019

Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients

Matevska-Geshkovska N, Staninova-Stojovska M, Kapedanovska-Nestorovska A, Petrushevska-Angelovska N, Panovski M, Grozdanovska B, Mitreski N, Dimovski A

Pharmacogenomics and Personalized Medicine 2018, 11:193-203

Published Date: 1 November 2018

CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort

Dagostino C, Allegri M, Napolioni V, D'Agnelli S, Bignami E, Mutti A, van Schaik RHN

Pharmacogenomics and Personalized Medicine 2018, 11:179-191

Published Date: 24 October 2018

Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients

Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Calderón-Ospina CA, Peña N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ

Pharmacogenomics and Personalized Medicine 2018, 11:169-178

Published Date: 16 October 2018

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty [Corrigendum]

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:167-168

Published Date: 26 September 2018

Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension

Sychev D, Shikh N, Morozova T, Grishina E, Ryzhikova K, Malova E

Pharmacogenomics and Personalized Medicine 2018, 11:157-165

Published Date: 20 September 2018

Qualitative user evaluation of a revised pharmacogenetic educational toolkit

Mills R, Haga SB

Pharmacogenomics and Personalized Medicine 2018, 11:139-146

Published Date: 4 September 2018

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:127-137

Published Date: 25 July 2018

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders

Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, Loonen AJM, Ivanova SA

Pharmacogenomics and Personalized Medicine 2018, 11:121-126

Published Date: 20 July 2018

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2018, 11:113-119

Published Date: 29 June 2018

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA

Pharmacogenomics and Personalized Medicine 2018, 11:107-112

Published Date: 18 June 2018

Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J

Pharmacogenomics and Personalized Medicine 2018, 11:95-106

Published Date: 8 June 2018

Emerging biomarkers in the diagnosis of prostate cancer

Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L

Pharmacogenomics and Personalized Medicine 2018, 11:83-94

Published Date: 16 May 2018

Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation

Asleh R, Briasoulis A, Berinstein EM, Wiener JB, Palla M, Kushwaha SS, Levy AP

Pharmacogenomics and Personalized Medicine 2018, 11:71-82

Published Date: 23 April 2018

H3Africa: current perspectives

Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, Ramsay M, Skelton M, Stein DJ

Pharmacogenomics and Personalized Medicine 2018, 11:59-66

Published Date: 10 April 2018

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment

Silvado CE, Terra VC, Twardowschy CA

Pharmacogenomics and Personalized Medicine 2018, 11:51-58

Published Date: 29 March 2018

Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO

Pharmacogenomics and Personalized Medicine 2018, 11:43-49

Published Date: 22 March 2018

The utility of pharmacogenetic testing to support the treatment of bipolar disorder

Ielmini M, Poloni N, Caselli I, Espadaler J, Tuson M, Grecchi A, Callegari C

Pharmacogenomics and Personalized Medicine 2018, 11:35-42

Published Date: 16 March 2018

The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction

Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2018, 11:1-5

Published Date: 28 December 2017

Ethiopian health care professionals’ knowledge, attitude, and interests toward pharmacogenomics

Abdela OA, Bhagavathula AS, Gebreyohannes EA, Tegegn HG

Pharmacogenomics and Personalized Medicine 2017, 10:279-285

Published Date: 5 December 2017

Pharmacogenomics of sickle cell disease: steps toward personalized medicine

Husain M, Hartman AD, Desai P

Pharmacogenomics and Personalized Medicine 2017, 10:261-265

Published Date: 19 October 2017

Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA

Pharmacogenomics and Personalized Medicine 2017, 10:253-259

Published Date: 27 September 2017

Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?

Rytkin E, Mirzaev KB, Grishina EA, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Giliarov MI, Andreev DA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:243-245

Published Date: 18 September 2017

ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine

Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, McLean M

Pharmacogenomics and Personalized Medicine 2017, 10:235-242

Published Date: 28 August 2017

Updating the landscape of direct-to-consumer pharmacogenomic testing

Filipski KK, Murphy JD, Helzlsouer KJ

Pharmacogenomics and Personalized Medicine 2017, 10:229-232

Published Date: 22 August 2017

CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications

St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:217-227

Published Date: 24 July 2017

Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder

Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:209-215

Published Date: 7 July 2017

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele

Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D

Pharmacogenomics and Personalized Medicine 2017, 10:205-208

Published Date: 20 June 2017

Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder

Brenton A, Richeimer S, Sharma M, Lee C, Kantorovich S, Blanchard J, Meshkin B

Pharmacogenomics and Personalized Medicine 2017, 10:187-195

Published Date: 18 May 2017

CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis

Laska AJ, Han MJ, Lospinoso JA, Brown PJ, Beachkofsky TM

Pharmacogenomics and Personalized Medicine 2017, 10:183-186

Published Date: 17 May 2017

DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion

Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H

Pharmacogenomics and Personalized Medicine 2017, 10:157-168

Published Date: 9 May 2017

ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches

Cleophas MC, Joosten LA, Stamp LK, Dalbeth N, Woodward OM, Merriman TR

Pharmacogenomics and Personalized Medicine 2017, 10:129-142

Published Date: 20 April 2017

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:107-114

Published Date: 12 April 2017

Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients

Salgado PC, Genvigir FDV, Felipe CR, Tedesco-Silva Jr H, Medina-Pestana JO, Doi SQ, Hirata MH, Hirata RDC

Pharmacogenomics and Personalized Medicine 2017, 10:101-106

Published Date: 31 March 2017

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA

Pharmacogenomics and Personalized Medicine 2017, 10:93-99

Published Date: 31 March 2017

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy

Umerez M, Gutierrez-Camino Á, Muñoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A

Pharmacogenomics and Personalized Medicine 2017, 10:69-78

Published Date: 27 March 2017

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

Takano M, Sugiyama T

Pharmacogenomics and Personalized Medicine 2017, 10:61-68

Published Date: 28 February 2017

Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review

Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE

Pharmacogenomics and Personalized Medicine 2017, 10:49-60

Published Date: 20 February 2017

Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6

Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:39-47

Published Date: 14 February 2017

The HLA-A*31:01 allele: influence on carbamazepine treatment

Yip VLM, Pirmohamed M

Pharmacogenomics and Personalized Medicine 2017, 10:29-38

Published Date: 31 January 2017

Prevalence of clinically actionable genotypes and medication exposure of older adults in the community

Daneshi N, Holliday E, Hancock S, Schneider JJ, Scott RJ, Attia J, Milward EA

Pharmacogenomics and Personalized Medicine 2017, 10:17-27

Published Date: 27 January 2017

Diet and lifestyle factors associated with miRNA expression in colorectal tissue

Slattery ML, Herrick JS, Mullany LE, Stevens JR, Wolff RK

Pharmacogenomics and Personalized Medicine 2017, 10:1-16

Published Date: 20 December 2016

CYP2D6 polymorphisms and their influence on risperidone treatment

Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C

Pharmacogenomics and Personalized Medicine 2016, 9:131-147

Published Date: 1 December 2016

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics

Lally J, Gaughran F, Timms P, Curran SR

Pharmacogenomics and Personalized Medicine 2016, 9:117-129

Published Date: 7 November 2016

Pharmacogenomics of statins: understanding susceptibility to adverse effects

Kitzmiller JP, Mikulik EB, Dauki AM, Mukherjee C, Luzum JA

Pharmacogenomics and Personalized Medicine 2016, 9:97-106

Published Date: 3 October 2016

Comments on Lucire and Crotty, 2011

Loonen AJM, Verkes RJ

Pharmacogenomics and Personalized Medicine 2016, 9:85-87

Published Date: 18 August 2016

Use of combinatorial pharmacogenomic testing in two cases from community psychiatry

Fields ES, Lorenz RA, Winner JG

Pharmacogenomics and Personalized Medicine 2016, 9:79-84

Published Date: 16 August 2016

The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia

Sychev DA, Shuev GN, Chertovskih JV, Maksimova NR, Grachev AV, Syrkova OA

Pharmacogenomics and Personalized Medicine 2016, 9:59-63

Published Date: 25 May 2016

The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment

Tulsyan S, Mittal RD, Mittal B

Pharmacogenomics and Personalized Medicine 2016, 9:47-58

Published Date: 27 April 2016

Potential utility of precision medicine for older adults with polypharmacy: a case series study

Finkelstein J, Friedman C, Hripcsak G, Cabrera M

Pharmacogenomics and Personalized Medicine 2016, 9:31-45

Published Date: 15 April 2016

Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility

Saldivar JS, Taylor D, Sugarman EA, Cullors A, Garces JA, Oades K, Centeno J

Pharmacogenomics and Personalized Medicine 2016, 9:1-6

Published Date: 19 January 2016

The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand

Bushyakanist A, Puangpetch A, Sukasem C, Kiertiburanakul S

Pharmacogenomics and Personalized Medicine 2015, 8:163-170

Published Date: 5 November 2015

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study

Damronglerd P, Sukasem C, Thipmontree W, Puangpetch A, Kiertiburanakul S

Pharmacogenomics and Personalized Medicine 2015, 8:155-162

Published Date: 3 October 2015

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

Balk JM, Haenen GRMM, Koc ÖM, Peters R, Bast A, van der Vijgh WJF, Koek GH

Pharmacogenomics and Personalized Medicine 2015, 8:137-144

Published Date: 12 August 2015

Olaparib in the management of ovarian cancer

Bixel K, Hays JL

Pharmacogenomics and Personalized Medicine 2015, 8:127-135

Published Date: 7 August 2015

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors

Sychev DA, Denisenko NP, Sizova ZM, Grachev AV, Velikolug KA

Pharmacogenomics and Personalized Medicine 2015, 8:111-114

Published Date: 27 May 2015

The current and future state of companion diagnostics

Agarwal A, Ressler D, Snyder G

Pharmacogenomics and Personalized Medicine 2015, 8:99-110

Published Date: 31 March 2015

Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T

Pharmacogenomics and Personalized Medicine 2015, 8:81-98

Published Date: 26 February 2015

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Richer AL, Friel JM, Carson VM, Inge LJ, Whitsett TG

Pharmacogenomics and Personalized Medicine 2015, 8:63-79

Published Date: 20 February 2015

Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists

Obara T, Abe S, Satoh M, Gutiérrez Ubeda SR, Yoshimachi S, Goto T

Pharmacogenomics and Personalized Medicine 2015, 8:35-41

Published Date: 29 January 2015

Targeted treatments for multiple myeloma: specific role of carfilzomib

Sugumar D, Keller J, Vij R

Pharmacogenomics and Personalized Medicine 2015, 8:23-33

Published Date: 20 January 2015

Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics

Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD

Pharmacogenomics and Personalized Medicine 2014, 7:399-409

Published Date: 12 December 2014

Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms

Pithukpakorn M, Tiwawanwong T, Lalerd Y, Assawamakin A, Premasathian N, Tasanarong A, Thongnoppakhun W, Vongwiwatana A

Pharmacogenomics and Personalized Medicine 2014, 7:379-385

Published Date: 5 December 2014

Clinical utility of pharmacogenomics in the management of hepatitis C

Trinks J, Hulaniuk ML, Redal MA, Flichman D

Pharmacogenomics and Personalized Medicine 2014, 7:339-347

Published Date: 20 October 2014

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

Sadeghi S, Olevsky O, Hurvitz SA

Pharmacogenomics and Personalized Medicine 2014, 7:329-338

Published Date: 15 October 2014

Pharmacogenetic information for patients on drug labels

Haga SB, Mills R, Moaddeb J

Pharmacogenomics and Personalized Medicine 2014, 7:297-305

Published Date: 3 October 2014

Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling

Femminella GD, Barrese V, Ferrara N, Rengo G

Pharmacogenomics and Personalized Medicine 2014, 7:267-273

Published Date: 9 September 2014

Developments in renal pharmacogenomics and applications in chronic kidney disease

Padullés A, Rama I, Llaudó I, Lloberas N

Pharmacogenomics and Personalized Medicine 2014, 7:251-266

Published Date: 28 August 2014

Simeprevir for the treatment of hepatitis C virus infection

Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E

Pharmacogenomics and Personalized Medicine 2014, 7:241-249

Published Date: 14 August 2014

Implementation and utilization of genetic testing in personalized medicine

Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA

Pharmacogenomics and Personalized Medicine 2014, 7:227-240

Published Date: 13 August 2014

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach

Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, Medea G

Pharmacogenomics and Personalized Medicine 2014, 7:129-136

Published Date: 19 June 2014

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N

Pharmacogenomics and Personalized Medicine 2014, 7:121-127

Published Date: 28 April 2014

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

Caruso A, Bellia C, Pivetti A, Agnello L, Bazza F, Scazzone C, Bivona G, Lo Sasso B, Ciaccio M

Pharmacogenomics and Personalized Medicine 2014, 7:117-120

Published Date: 2 April 2014

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G

Pharmacogenomics and Personalized Medicine 2014, 7:107-116

Published Date: 27 March 2014

Precision medicine and personalized breast cancer: combination pertuzumab therapy

Reynolds K, Sarangi S, Bardia A, Dizon DS

Pharmacogenomics and Personalized Medicine 2014, 7:95-105

Published Date: 20 March 2014

ALK-driven tumors and targeted therapy: focus on crizotinib

Murga-Zamalloa C, Lim MS

Pharmacogenomics and Personalized Medicine 2014, 7:87-94

Published Date: 20 March 2014

Glioblastoma extracellular vesicles: reservoirs of potential biomarkers

Redzic JS, Ung TH, Graner MW

Pharmacogenomics and Personalized Medicine 2014, 7:65-77

Published Date: 13 February 2014

Molecular variants and mutations in medulloblastoma

Schroeder K, Gururangan S

Pharmacogenomics and Personalized Medicine 2014, 7:43-51

Published Date: 4 February 2014

Dabrafenib for treatment of BRAF-mutant melanoma

Kainthla R, Kim KB, Falchook GS

Pharmacogenomics and Personalized Medicine 2014, 7:21-29

Published Date: 31 December 2013

Delivering pharmacogenetic testing in a primary care setting

Mills R, Voora D, Peyser B, Haga SB

Pharmacogenomics and Personalized Medicine 2013, 6:105-112

Published Date: 18 September 2013

Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue

Penney RB, Lundgreen A, Yao-Borengasser A, Koroth-Edavana V, Williams S, Wolff R, Slattery ML, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:99-103

Published Date: 9 September 2013

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen

Sensorn I, Sirachainan E, Chamnanphol M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D

Pharmacogenomics and Personalized Medicine 2013, 6:93-98

Published Date: 26 August 2013

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors

Sukasem C, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P

Pharmacogenomics and Personalized Medicine 2013, 6:85-91

Published Date: 22 August 2013

ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro

Skoglund K, Boiso Moreno S, Baytar M, Jönsson JI, Gréen H

Pharmacogenomics and Personalized Medicine 2013, 6:63-72

Published Date: 20 August 2013

Molecular targeted therapies in metastatic melanoma

Chakraborty R, Wieland CN, Comfere NI

Pharmacogenomics and Personalized Medicine 2013, 6:49-56

Published Date: 7 June 2013

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C

Pharmacogenomics and Personalized Medicine 2013, 6:37-48

Published Date: 24 May 2013

Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA

Pharmacogenomics and Personalized Medicine 2013, 6:25-36

Published Date: 4 April 2013

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects

Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:19-24

Published Date: 6 March 2013

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF

Pharmacogenomics and Personalized Medicine 2013, 6:9-17

Published Date: 1 March 2013

Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report

Tan-kam T, Suthisisang C, Pavasuthipaisit C, Limsila P, Puangpetch A, Sukasem C

Pharmacogenomics and Personalized Medicine 2013, 6:3-7

Published Date: 11 January 2013

Pharmacogenomic considerations in opioid analgesia. [Corrigendum]

Vuilleumier PH, Stamer UM, Landau R

Pharmacogenomics and Personalized Medicine 2013, 6:1-2

Published Date: 14 January 2013

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C

Pharmacogenomics and Personalized Medicine 2012, 5:149-153

Published Date: 17 October 2012

Drug targets and predictive biomarkers in the management of metastatic melanoma

Thumar J, Giesen E, Kluger HM

Pharmacogenomics and Personalized Medicine 2012, 5:139-148

Published Date: 28 September 2012

Boceprevir and personalized medicine in hepatitis C virus infection

Habersetzer F, Leboeuf C, Doffoël M, Baumert TF

Pharmacogenomics and Personalized Medicine 2012, 5:125-137

Published Date: 26 September 2012

Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent

AL-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK

Pharmacogenomics and Personalized Medicine 2012, 5:99-111

Published Date: 7 September 2012

Role of pharmacogenomics in the treatment of tuberculosis: a review

Ramachandran G, Swaminathan S

Pharmacogenomics and Personalized Medicine 2012, 5:89-98

Published Date: 13 September 2012

Pharmacogenomic considerations in opioid analgesia

Vuilleumier PH, Stamer UM, Landau R

Pharmacogenomics and Personalized Medicine 2012, 5:73-87

Published Date: 23 August 2012

ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics

Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA

Pharmacogenomics and Personalized Medicine 2012, 5:53-62

Published Date: 18 April 2012

Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy

Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM

Pharmacogenomics and Personalized Medicine 2012, 5:19-35

Published Date: 13 January 2012

Individualization of antiretroviral therapy

Pavlos R, Phillips EJ

Pharmacogenomics and Personalized Medicine 2012, 5:1-17

Published Date: 29 December 2011

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S

Pharmacogenomics and Personalized Medicine 2011, 4:137-145

Published Date: 17 November 2011

Role of cytochrome P450 genotype in the steps toward personalized drug therapy

Cavallari LH, Jeong H, Bress A

Pharmacogenomics and Personalized Medicine 2011, 4:123-136

Published Date: 7 November 2011

Clinical implementation of RNA signatures for pharmacogenomic decision-making

Tang W, Hu Z, Muallem H, Gulley ML

Pharmacogenomics and Personalized Medicine 2011, 4:95-107

Published Date: 8 September 2011

Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain

Wallace TJM, Zai CC, Brandl EJ, Müller DJ

Pharmacogenomics and Personalized Medicine 2011, 4:83-93

Published Date: 18 August 2011

ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer

Vaezi A, Feldman CH, Niedernhofer LJ

Pharmacogenomics and Personalized Medicine 2011, 4:47-63

Published Date: 20 July 2011

A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross

Gelinas R, Chesler EJ, Vasconcelos D, Miller DR, Yuan Y, Wang K, Galas D

Pharmacogenomics and Personalized Medicine 2011, 4:35-45

Published Date: 4 July 2011

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

Pietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, et al

Pharmacogenomics and Personalized Medicine 2011, 4:1-9

Published Date: 14 March 2011

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

Sarah Rofaiel, Esther N Muo, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2010, 3:129-143

Published Date: 17 September 2010

The future role of personalized medicine in the treatment of glioblastoma multiforme

Jing Li, Chunhui Di, Austin K Mattox, et al

Pharmacogenomics and Personalized Medicine 2010, 3:111-127

Published Date: 19 August 2010

Antiplatelet agents and proton pump inhibitors – personalizing treatment

Eugene Lin, Rajiv Padmanabhan, Majaz Moonis

Pharmacogenomics and Personalized Medicine 2010, 3:101-109

Published Date: 28 June 2010

Impact of genetic polymorphisms on clinical response to antithrombotics

Kena J Lanham, Julie H Oestreich, Steven P Dunn, et al

Pharmacogenomics and Personalized Medicine 2010, 3:87-99

Published Date: 18 June 2010

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab

Naveed Wagle, Leia Nghiemphu, Albert Lai, et al

Pharmacogenomics and Personalized Medicine 2010, 3:79-85

Published Date: 9 June 2010

DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics

Darko Turic, James Swanson, Edmund Sonuga-Barke

Pharmacogenomics and Personalized Medicine 2010, 3:61-78

Published Date: 21 May 2010

Determinants to optimize response to clopidogrel in acute coronary syndrome

Betti Giusti, Anna Maria Gori, Rossella Marcucci, et al

Pharmacogenomics and Personalized Medicine 2010, 3:33-50

Published Date: 8 April 2010

Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

Peter Avery, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:79-91

Published Date: 13 September 2009

Pharmacogenomics in osteoporosis: Steps toward personalized medicine

Robert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al

Pharmacogenomics and Personalized Medicine 2009, 2:69-78

Published Date: 10 September 2009

Genomics and proteomics: Applications in autoimmune diseases

Wolfgang Hueber, William H Robinson

Pharmacogenomics and Personalized Medicine 2009, 2:39-48

Published Date: 17 August 2009

Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid  dependence: A meta-analysis

Janet K Coller, Julia Beardsley, James Bignold, Yibai Li, Florence Merg, et al

Pharmacogenomics and Personalized Medicine 2009, 2:9-19

Published Date: 20 March 2009

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Avery Schwartz, Shany Blum, Rabea Asleh, Mordechai Pollak, Shiri Kalet-Litman, Andrew P Levy

Pharmacogenomics and Personalized Medicine 2009, 2:1-8

Published Date: 27 February 2009

Integrating epigenomics into pharmacogenomic studies

Wei Zhang, R Stephanie Huang, M Eileen Dolan

Pharmacogenomics and Personalized Medicine 2008, 1:7-14

Published Date: 2 November 2008